RE: Priced in, a downgrade was expected30 Jan 2024 11:50
Walkie - I think this is a good recovery play over a 3 year period - they have decent market size and positioning - so the shares really could multiply if/when things improve. But given the debt, it is likely to be a bumpy and unpredictable ride short term - and I don’t think anyone has a great crystal ball predicting those bumps. Is it worth the wait? There are multiple valuation perspectives that suggest so IMO. I note the enterprise value is now around £750m - that’s around half what they paid for Eastman and Omnova combined - and that’s before mentioning the legacy business. So it seems a lot is priced in. Another perspective is on a recovered EBITDA multiple - they are still emphasising that £300m EBITDA is possible - put that on a conservative 6x and the equity is worth around 750p a share. The risks obviously are that things deteriorate further, they breach covenants and we get going concern warnings etc. But the banks have thus far proven supportive, recently extending terms to 2027, and they must be aware that chemical companies experience downturns as well as upturns. So it seems good risk/reward to me - but to repeat, I thought that at 70p old money too! GLA